BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33965292)

  • 21. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
    Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
    Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.
    Saba K; Wettstein MS; Lieger L; Hötker AM; Donati OF; Moch H; Ankerst DP; Poyet C; Sulser T; Eberli D; Mortezavi A
    J Urol; 2020 Apr; 203(4):719-726. PubMed ID: 31651228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. How to implement magnetic resonance imaging before prostate biopsy in clinical practice: nomograms for saving biopsies.
    Borque-Fernando Á; Esteban LM; Celma A; Roche S; Planas J; Regis L; de Torres I; Semidey ME; Trilla E; Morote J
    World J Urol; 2020 Jun; 38(6):1481-1491. PubMed ID: 31506748
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External validation of Cormio nomogram for predicting all prostate cancers and clinically significant prostate cancers.
    Cindolo L; Bertolo R; Minervini A; Sessa F; Muto G; Bove P; Vittori M; Bozzini G; Castellan P; Mugavero F; Falsaperla M; Schips L; Celia A; Bada M; Porreca A; Pastore A; Al Salhi Y; Giampaoli M; Novella G; Rizzetto R; Trabacchin N; Mantica G; Pini G; Lombardo R; Tubaro A; Antonelli A; De Nunzio C
    World J Urol; 2020 Oct; 38(10):2555-2561. PubMed ID: 31907633
    [TBL] [Abstract][Full Text] [Related]  

  • 25. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction.
    Püllen L; Radtke JP; Wiesenfarth M; Roobol MJ; Verbeek JFM; Wetter A; Guberina N; Pandey A; Hüttenbrink C; Tschirdewahn S; Pahernik S; Hadaschik BA; Distler FA
    BJU Int; 2020 Mar; 125(3):407-416. PubMed ID: 31758738
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
    Doan P; Graham P; Lahoud J; Remmers S; Roobol MJ; Kim L; Patel MI
    BJU Int; 2021 Dec; 128 Suppl 3():36-44. PubMed ID: 34374190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy.
    Nyarangi-Dix J; Wiesenfarth M; Bonekamp D; Hitthaler B; Schütz V; Dieffenbacher S; Mueller-Wolf M; Roth W; Stenzinger A; Duensing S; Roethke M; Teber D; Schlemmer HP; Hohenfellner M; Radtke JP
    Eur Urol Focus; 2020 Nov; 6(6):1205-1212. PubMed ID: 30477971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Roumiguié M; Fossati N; Stabile A; Beauval JB; Malavaud B; Scuderi S; Barletta F; Moschini M; Zamboni S; Rakauskas A; Tian Z; Karakiewicz PI; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
    Eur Urol; 2020 Jun; 77(6):733-741. PubMed ID: 31547938
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External validation of the Memorial Sloan Kettering Cancer Centre and Briganti nomograms for the prediction of lymph node involvement of prostate cancer using clinical stage assessed by magnetic resonance imaging.
    Soeterik TFW; Hueting TA; Israel B; van Melick HHE; Dijksman LM; Stomps S; Biesma DH; Koffijberg H; Sedelaar M; Witjes JA; van Basten JA
    BJU Int; 2021 Aug; 128(2):236-243. PubMed ID: 33630398
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Single-parameter, Structure-based IsoPSA Assay Demonstrates Improved Diagnostic Accuracy for Detection of Any Prostate Cancer and High-grade Prostate Cancer Compared to a Concentration-based Assay of Total Prostate-specific Antigen: A Preliminary Report.
    Klein EA; Chait A; Hafron JM; Kernen KM; Manickam K; Stephenson AJ; Wagner M; Zhu H; Kestranek A; Zaslavsky B; Stovsky M
    Eur Urol; 2017 Dec; 72(6):942-949. PubMed ID: 28396176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of immune PSA complex (iXip) in the prediction of prostate cancer.
    Lombardo R; Tema G; Cancrini F; Albanesi L; Mavilla L; Tariciotti P; Gentile BC; Aloisi P; Rizzo G; Tardioli S; Giulianelli R
    Biomarkers; 2021 Feb; 26(1):26-30. PubMed ID: 33100063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of metabolic syndrome in high grade prostate cancer: development of a clinical nomogram.
    De Nunzio C; Tema G; Lombardo R; Cicione A; Dell'''''Oglio P; Tubaro A
    Minerva Urol Nefrol; 2020 Dec; 72(6):729-736. PubMed ID: 32748618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. External Validation of a Multiparametric Magnetic Resonance Imaging-based Nomogram for the Prediction of Extracapsular Extension and Seminal Vesicle Invasion in Prostate Cancer Patients Undergoing Radical Prostatectomy.
    Diamand R; Ploussard G; Roumiguié M; Oderda M; Benamran D; Fiard G; Quackels T; Assenmacher G; Simone G; Van Damme J; Malavaud B; Iselin C; Descotes JL; Roche JB; Peltier A; Roumeguère T; Albisinni S
    Eur Urol; 2021 Feb; 79(2):180-185. PubMed ID: 33023770
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies.
    Gandaglia G; Ploussard G; Valerio M; Mattei A; Fiori C; Fossati N; Stabile A; Beauval JB; Malavaud B; Roumiguié M; Robesti D; Dell'Oglio P; Moschini M; Zamboni S; Rakauskas A; De Cobelli F; Porpiglia F; Montorsi F; Briganti A
    Eur Urol; 2019 Mar; 75(3):506-514. PubMed ID: 30342844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
    Panebianco V; Barchetti G; Simone G; Del Monte M; Ciardi A; Grompone MD; Campa R; Indino EL; Barchetti F; Sciarra A; Leonardo C; Gallucci M; Catalano C
    Eur Urol; 2018 Jul; 74(1):48-54. PubMed ID: 29566957
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expanding Active Surveillance Criteria for Low- and Intermediate-risk Prostate Cancer: Can We Accurately Predict the Risk of Misclassification for Patients Diagnosed by Multiparametric Magnetic Resonance Imaging-targeted Biopsy?
    Diamand R; Albisinni S; Roche JB; Lievore E; Lacetera V; Chiacchio G; Beatrici V; Mastroianni R; Simone G; Windisch O; Benamran D; Fourcade A; An Nguyen T; Fournier G; Fiard G; Ploussard G; Peltier A; Roumeguère T
    Eur Urol Focus; 2023 Mar; 9(2):298-302. PubMed ID: 36210296
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multivariate risk prediction tools including MRI for individualized biopsy decision in prostate cancer diagnosis: current status and future directions.
    Schoots IG; Roobol MJ
    World J Urol; 2020 Mar; 38(3):517-529. PubMed ID: 30868240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. External validation of the Rotterdam prostate cancer risk calculator within a high-risk Dutch clinical cohort.
    Hagens MJ; Stelwagen PJ; Veerman H; Rynja SP; Smeenge M; van der Noort V; Roeleveld TA; van Kesteren J; Remmers S; Roobol MJ; van Leeuwen PJ; van der Poel HG
    World J Urol; 2023 Jan; 41(1):13-18. PubMed ID: 36245015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.